Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Cancer and Blood Specialists-Tenaya
2372
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Cancer and Blood Specialists-Tenaya
2372
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Northwest
2372
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Northwest
2372
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
2372
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
2372
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
2375
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
2375
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Summerlin Hospital Medical Center
2367
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Summerlin Hospital Medical Center
2367
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Las Vegas Cancer Center-Medical Center
2377
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Las Vegas Cancer Center-Medical Center
2377
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Fort Apache
2377
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Fort Apache
2377
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
2377
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
2377
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
2372
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
2372
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
University Cancer Center
2367
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
University Cancer Center
2367
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Vegas Tenaya
2366
mi
from 02139
Las Vegas, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Vegas Tenaya
2366
mi
from 02139
Las Vegas, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Renown Regional Medical Center
2513
mi
from 02139
Reno, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Renown Regional Medical Center
2513
mi
from 02139
Reno, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Alpine Hematology-Oncology
2515
mi
from 02139
Reno, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Alpine Hematology-Oncology
2515
mi
from 02139
Reno, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Saint Mary's Regional Medical Center
2515
mi
from 02139
Reno, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Saint Mary's Regional Medical Center
2515
mi
from 02139
Reno, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Associates
2515
mi
from 02139
Reno, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Associates
2515
mi
from 02139
Reno, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Reno Oncology Consultants
2518
mi
from 02139
Reno, NV
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Reno Oncology Consultants
2518
mi
from 02139
Reno, NV
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
New Hampshire Oncology Hematology PA-Concord
62
mi
from 02139
Concord, NH
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
New Hampshire Oncology Hematology PA-Concord
62
mi
from 02139
Concord, NH
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
New Hampshire Oncology - Hematology, PA - Hooksett
53
mi
from 02139
Hooksett, NH
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
New Hampshire Oncology - Hematology, PA - Hooksett
53
mi
from 02139
Hooksett, NH
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
LRGHealthcare-Lakes Region General Hospital
82
mi
from 02139
Laconia, NH
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
LRGHealthcare-Lakes Region General Hospital
82
mi
from 02139
Laconia, NH
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
105
mi
from 02139
Lebanon, NH
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
105
mi
from 02139
Lebanon, NH
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Norris Cotton Cancer Center-Manchester
47
mi
from 02139
Manchester, NH
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Norris Cotton Cancer Center-Manchester
47
mi
from 02139
Manchester, NH
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Veterans Adminstration New Jersey Health Care System
195
mi
from 02139
East Orange, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Veterans Adminstration New Jersey Health Care System
195
mi
from 02139
East Orange, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Southern Ocean County Medical Center
247
mi
from 02139
Manahawkin, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Southern Ocean County Medical Center
247
mi
from 02139
Manahawkin, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Morristown Medical Center
205
mi
from 02139
Morristown, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Morristown Medical Center
205
mi
from 02139
Morristown, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Virtua Memorial
252
mi
from 02139
Mount Holly, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Virtua Memorial
252
mi
from 02139
Mount Holly, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Newark Beth Israel Medical Center
194
mi
from 02139
Newark, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Newark Beth Israel Medical Center
194
mi
from 02139
Newark, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Riverview Medical Center/Booker Cancer Center
207
mi
from 02139
Red Bank, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Riverview Medical Center/Booker Cancer Center
207
mi
from 02139
Red Bank, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Robert Wood Johnson University Hospital Somerset
219
mi
from 02139
Somerville, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Robert Wood Johnson University Hospital Somerset
219
mi
from 02139
Somerville, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Overlook Hospital
203
mi
from 02139
Summit, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Overlook Hospital
203
mi
from 02139
Summit, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Virtua Voorhees
264
mi
from 02139
Voorhees, NJ
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Virtua Voorhees
264
mi
from 02139
Voorhees, NJ
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Lovelace Medical Center - Downtown
1965
mi
from 02139
Albuquerque, NM
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Lovelace Medical Center - Downtown
1965
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
1963
mi
from 02139
Albuquerque, NM
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
1963
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
New Mexico Oncology Hematology Consultants
1959
mi
from 02139
Albuquerque, NM
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
New Mexico Oncology Hematology Consultants
1959
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center - Las Cruces
2061
mi
from 02139
Las Cruces, NM
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center - Las Cruces
2061
mi
from 02139
Las Cruces, NM
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC at Albany Medical Center
138
mi
from 02139
Albany, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC at Albany Medical Center
138
mi
from 02139
Albany, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
State University of New York - Downstate Medical Center
188
mi
from 02139
Brooklyn, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
State University of New York - Downstate Medical Center
188
mi
from 02139
Brooklyn, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
396
mi
from 02139
Buffalo, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
396
mi
from 02139
Buffalo, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Mary Imogene Bassett Hospital
195
mi
from 02139
Cooperstown, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Mary Imogene Bassett Hospital
195
mi
from 02139
Cooperstown, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Arnot Ogden Medical Center/Falck Cancer Center
294
mi
from 02139
Elmira, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Arnot Ogden Medical Center/Falck Cancer Center
294
mi
from 02139
Elmira, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Glens Falls Hospital
144
mi
from 02139
Glens Falls, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Glens Falls Hospital
144
mi
from 02139
Glens Falls, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Orange Regional Medical Center
182
mi
from 02139
Middletown, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Orange Regional Medical Center
182
mi
from 02139
Middletown, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
North Shore-LIJ Health System/Center for Advanced Medicine
174
mi
from 02139
New Hyde Park, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
North Shore-LIJ Health System/Center for Advanced Medicine
174
mi
from 02139
New Hyde Park, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Beth Israel Med Ctr
186
mi
from 02139
New York, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Beth Israel Med Ctr
186
mi
from 02139
New York, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
180
mi
from 02139
New York, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
180
mi
from 02139
New York, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Highland Hospital
333
mi
from 02139
Rochester, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Highland Hospital
333
mi
from 02139
Rochester, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
University of Rochester
335
mi
from 02139
Rochester, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
University of Rochester
335
mi
from 02139
Rochester, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Medical Center
127
mi
from 02139
Stony Brook, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Medical Center
127
mi
from 02139
Stony Brook, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
State University of New York Upstate Medical University
256
mi
from 02139
Syracuse, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
State University of New York Upstate Medical University
256
mi
from 02139
Syracuse, NY
Click here to add this to my saved trials
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated:  12/31/1969
Faxton-Saint Luke's Healthcare
216
mi
from 02139
Utica, NY
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Status: Enrolling
Updated: 12/31/1969
Faxton-Saint Luke's Healthcare
216
mi
from 02139
Utica, NY
Click here to add this to my saved trials